Rachel Narozniak, MA

Articles

Immunotherapy Use Does Not Correlate With Increased Mortality in Patients with COVID-19, Cancer

July 20th 2020

Treatment with immune checkpoint inhibitors did not increase the risk of mortality in patients with COVID-19 and cancer.

Ramucirumab Combination Expands Lung Cancer Options

July 16th 2020

Edgardo Santos, MD, discusses the FDA approval of ramucirumab plus erlotinib for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.

New Indication Propels Brigatinib Into the Front Line for ALK-Positive NSCLC

July 15th 2020

Thomas E. Stinchcombe, MD, discusses brigatinib’s mechanism as well as the next steps to advance the treatment paradigm for patients with ALK-positive NSCLC.

Beyond Cancer Type: New Pan-Tumor Targets Emerge

July 7th 2020

The growing use of genomic profiling technologies will help promote the development of anticancer therapies based on molecular features of a tumor rather than the body site of origin.

Olaparib Plus Bevacizumab Combination Expands Options in HRD+ Cancer

July 4th 2020

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma

July 3rd 2020

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors

July 3rd 2020

EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.

Regimen Doubles Down on Immunotherapy to Improve NSCLC Outcomes

July 2nd 2020

Suresh S. Ramalingam, MD, discusses the combination of nivolumab and ipilimumab in metastatic non–small cell lung cancer.

Investigators Strive to Refine Paradigm for Penile Cancer Treatment

June 24th 2020

Investigators are using a novel clinical trial design to test multiple treatment strategies in an effort to define the standard of care in squamous cell carcinoma of the penis.

COVID-19 Pandemic Accelerates RWD-Based Initiatives in Oncology

June 23rd 2020

The FDA is presently spearheading several initiatives in light of COVID-19 aimed at refining the role of RWD in cancer care to guide clinical trial development, procure answers to pressing clinical questions, and support regulatory decisions for in vitro diagnostics.

Lipophilic Statin Use Is Associated With Decreased Mortality in Epithelial Ovarian Cancer

June 22nd 2020

Findings from an observational study of more than 10,000 women with ovarian cancer showed that lipophilic statins were associated with a 43% overall reduction in epithelial ovarian cancer mortality, with declines seen across subtypes.

Oncology Centers Examine the Aftermath of COVID-19 on Clinical Trials

June 19th 2020

Institutions are slowly but steadily resuming their investigational efforts, examining both the temporary and lasting effects the pandemic has left on their centers.

Niraparib’s Indication Expands in Ovarian Cancer

June 19th 2020

Bhavana Pothuri, MD, discusses the practice-changing implications of niraparib’s approval in ovarian cancer.

Dual Checkpoint Regimen Buoys Prospects for Immunotherapy in HCC

June 18th 2020

The recent approval of nivolumab in combination with ipilimumab demonstrates the utility of dual immunotherapy for patients with hepatocellular carcinoma.

MIBC Trial Pairs 2 Immunotherapy Agents

June 5th 2020

Investigators are testing whether the addition of inhibitors targeting the PD-1 and IDO immune pathways to standard chemotherapy in the neoadjuvant setting will offer superior outcomes for patients with muscle-invasive bladder cancer.

Sacituzumab Govitecan Becomes First ADC Approved for TNBC

June 3rd 2020

Aditya Bardia, MD, MPH, discusses how the antibody-drug conjugate sacituzumab govitecan-hziy can address the unmet need in metastatic triple-negative breast cancer and the toxicities seen with the therapy.

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma

May 31st 2020

The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.

5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma

May 30th 2020

Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma.

Top Priorities Outlined in Next Decade of Breast Cancer Research

May 26th 2020

Developing diagnostics to identify the molecular drivers of breast cancer and model the mechanisms of disease progression will be a key priority of the investigative efforts aimed at improving patient outcomes in the field over the next decade.

Tucatinib Approval Adds Impact to HER2+ Breast Cancer Paradigm

May 15th 2020

Therapeutic options for pretreated HER2-positive breast cancer now include tucatinib (Tukysa) as part of a triplet regimen with a tolerable safety profile that promises improved quality of life.